Have a feature idea you'd love to see implemented?
Let us know!
SWTX SpringWorks Therapeutics Inc
Price (delayed)
$36.3
Market cap
$2.7B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.89
Enterprise value
$2.62B
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks
Highlights
SpringWorks Therapeutics's revenue has soared by 57% from the previous quarter
The gross profit has soared by 56% from the previous quarter
SpringWorks Therapeutics's equity has increased by 35% YoY but it has decreased by 4.3% QoQ
SWTX's quick ratio is down by 31% year-on-year and by 23% since the previous quarter
Key stats
What are the main financial stats of SWTX
Market
Valuations
Earnings
Shares outstanding
74.39M
Market cap
$2.7B
Enterprise value
$2.62B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.06
Price to sales (P/S)
19.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.35
Revenue
$135.49M
EBIT
-$275.16M
EBITDA
-$270.17M
Free cash flow
-$209.9M
Per share
Balance sheet
Liquidity
EPS
-$3.89
Free cash flow per share
-$2.83
Book value per share
$7.17
Revenue per share
$1.82
TBVPS
$8.2
Total assets
$608.88M
Total liabilities
$76.3M
Debt
$6.91M
Equity
$532.58M
Working capital
$364.5M
Debt to equity
0.01
Current ratio
6.16
Quick ratio
5.81
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
-199.4%
Gross margin
94.5%
Net margin
-203.1%
Operating margin
-217.9%
Return on assets
-42.2%
Return on equity
-48.2%
Return on invested capital
-57.8%
Return on capital employed
-51.1%
Return on sales
-203.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SWTX stock price
How has the SpringWorks Therapeutics stock price performed over time
Intraday
-3.04%
1 week
-0.68%
1 month
19.06%
1 year
71.63%
YTD
-0.55%
QTD
13.3%
Financial performance
How have SpringWorks Therapeutics's revenue and profit performed over time
Revenue
$135.49M
Gross profit
$128.07M
Operating income
-$295.25M
Net income
-$275.16M
Gross margin
94.5%
Net margin
-203.1%
SpringWorks Therapeutics's revenue has soared by 57% from the previous quarter
The gross profit has soared by 56% from the previous quarter
SWTX's net margin is up by 42% since the previous quarter
SWTX's operating margin is up by 42% from the previous quarter
Growth
What is SpringWorks Therapeutics's growth rate over time
Valuation
What is SpringWorks Therapeutics stock price valuation
P/E
N/A
P/B
5.06
P/S
19.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.35
SWTX's EPS is up by 20% YoY and by 12% from the previous quarter
SpringWorks Therapeutics's equity has increased by 35% YoY but it has decreased by 4.3% QoQ
The P/B is 3.3% above the last 4 quarters average of 4.9 but 2.7% below the 5-year quarterly average of 5.2
SWTX's P/S is 87% below its last 4 quarters average of 152.6
SpringWorks Therapeutics's revenue has soared by 57% from the previous quarter
Efficiency
How efficient is SpringWorks Therapeutics business performance
SWTX's ROS is up by 42% from the previous quarter
The ROE has grown by 24% YoY and by 14% from the previous quarter
SWTX's ROA is up by 24% YoY and by 14% from the previous quarter
The company's return on invested capital rose by 22% YoY and by 15% QoQ
Dividends
What is SWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SWTX.
Financial health
How did SpringWorks Therapeutics financials performed over time
SWTX's quick ratio is down by 31% year-on-year and by 23% since the previous quarter
SpringWorks Therapeutics's total assets has increased by 30% YoY
SWTX's debt is 99% smaller than its equity
The debt to equity has plunged by 50% YoY
SpringWorks Therapeutics's equity has increased by 35% YoY but it has decreased by 4.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.